



## Final Appraisal Recommendation

Advice No: 3514 – November 2014

**Umeclidinium (Incruse<sup>®</sup>▼) 55 micrograms inhalation powder**

**Submission by GlaxoSmithKline UK**

### Recommendation of AWMSG

**Umeclidinium (Incruse<sup>®</sup>▼) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.**

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1352), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	GlaxoSmithKline UK
Date of first issue	November 2014
Last reviewed	December 2017

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3514:  
Umeclidinium (Incruse<sup>®</sup>▼) 55 micrograms inhalation powder. November 2014.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).